SCHEMBL1685393

SCHEMBL1685393

CC(C)(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.54
PBRM1 Q86U86 1/20 0.50
GPR84 Q9NQS5 4/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
CYP3A4 P08684 2/20 0.47
MAPT P10636 1/20 0.47
AHR P35869 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPK1 P28482 1/20 0.46
NR4A2 P43354 1/20 0.46
CREBBP Q92793 1/20 0.46
ALDH1A1 P00352 3/20 0.46
FFAR1 O14842 1/20 0.46
CFTR P13569 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13335152 0.87 ATM (0.54) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL29885789 0.87 ATM (0.54) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL799601 0.87 ATM (0.54) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL30437029 0.87 ATM (0.54) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL7192679 0.83 ATM (0.50) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL11797189 0.83 ATM (0.50) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL17232880 0.83 ATM (0.50) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL28864004 0.82 ATM (0.52) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL23478771 0.80 ATM (0.47) ATMPBRM1GPR84KMT2AMEN1
SCHEMBL19059561 0.80 GPR84 (0.47) ATMGPR84KMT2AMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1328513-A2 DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS The Texas A & M University System (US) 2003-07-23 EP claimed
WO-2002028832-A2 DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS THE TEXAS A & M UNIVERSITY SYSTEM (US) 2002-04-11 WO claimed
EP-0971890-A2 SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2000-01-19 EP claimed
WO-1998050357-A2 SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS THE TEXAS A & M UNIVERSITY SYSTEM (US) 1998-11-12 WO claimed
US-9472769-B2 Organic electroluminescent device UDC IRELAND LIMITED (IE) 2016-10-18 US disclosed
US-9472769-B2 Organic electroluminescent device UDC IRELAND LIMITED (IE) 2016-10-18 US disclosed
CN-103880728-B A kind of method preparing di-indole methyl hydride compounds TAIZHOU UNIVERSITY (CN) 2016-03-30 CN disclosed
US-20150263296-A1 Organic Electroluminescent Device UDC IRELAND LTD (IE) 2015-09-17 US disclosed
US-20150263296-A1 Organic Electroluminescent Device UDC IRELAND LTD (IE) 2015-09-17 US disclosed
US-8890122-B2 Organic electroluminescent device UDC IRELAND LIMITED (IE) 2014-11-18 US disclosed
US-8890122-B2 Organic electroluminescent device UDC IRELAND LIMITED (IE) 2014-11-18 US disclosed
CN-103880728-A Method for preparing diindolylmethane compound UNIV TAIZHOU 2014-06-25 CN disclosed
EP-1811842-A2 3,3'-DIINDOLYLMETHANE IMMUNE ACTIVATING COMPOSITIONS The Regents of the University of California (US) 2007-08-01 EP disclosed
WO-2006110299-A1 3,3'-DIINDOLYLMETHANE COMPOSITIONS INHIBIT ANGIOGENESIS REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-10-19 WO disclosed
US-20060229355-A1 3.3'-Diindolylmethane compositions inhibit angiogenesis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2006-10-12 US disclosed
WO-2006068713-A2 3,3'-DIINDOLYLMETHANE IMMUNE ACTIVATING COMPOSITIONS REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-06-29 WO disclosed
EP-1328513-A2 DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS The Texas A & M University System (US) 2003-07-23 EP disclosed
WO-2002028832-A2 DIINDOLYLMETHANE AND C-SUBSTITUTED DIINDOLYLMETHANE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE CANCERS THE TEXAS A & M UNIVERSITY SYSTEM (US) 2002-04-11 WO disclosed
EP-0971890-A2 SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2000-01-19 EP disclosed
WO-1998050357-A2 SUBSTITUTED ANALOGS OF INDOLE-3-CARBINOL AND OF DIINDOLYMETHANE AS ANTIESTROGENS THE TEXAS A & M UNIVERSITY SYSTEM (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229355-A1 3.3'-Diindolylmethane compositions inhibit angiogenesis FLT4, FLT1, PGF ATM 4804/4885PBRM1 1619/4885GPR84 1844/4885
US-20150263296-A1 Organic Electroluminescent Device IDO1, L1CAM, IDO2 ATM 3037/4885PBRM1 3538/4885GPR84 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.